Cargando…
A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19
BACKGROUND: The outbreak of a new coronavirus (SARS-CoV-2) poses a great challenge to global public health. New and effective intervention strategies are urgently needed to combat the disease. METHODS: We conducted an open-label, non-randomized, clinical trial involving moderate COVID-19 patients ac...
Autores principales: | Fu, Weihui, Liu, Yan, Xia, Lu, Li, Min, Song, Zhigang, Hu, Huiliang, Yang, Zongguo, Wang, Lin, Cheng, Xiaobo, Wang, Mei, Jiang, Rongrong, Liu, Li, Mao, Xiaoting, Chen, Jun, Ling, Yun, Zhang, Lin, Yan, Jin, Shan, Fei, Steinhart, Corklin, Zhang, Xiaoyan, Zhu, Tongyu, Xu, Jianqing, Lu, Hongzhou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388798/ https://www.ncbi.nlm.nih.gov/pubmed/32838238 http://dx.doi.org/10.1016/j.eclinm.2020.100478 |
Ejemplares similares
-
An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19
por: Fu, Weihui, et al.
Publicado: (2020) -
A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19
por: Liu, Yan, et al.
Publicado: (2022) -
IFNγ-dependent silencing of TFF1 during Helicobacter pylori infection
por: Eletto, D., et al.
Publicado: (2022) -
Validation of the DNA Methylation Landscape of TFF1/TFF2 in Gastric Cancer
por: Qian, Ze, et al.
Publicado: (2022) -
Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients
por: Wang, Zhenyan, et al.
Publicado: (2021)